These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 36671792)

  • 1. Landscape of Push Funding in Antibiotic Research: Current Status and Way Forward.
    Wasan H; Singh D; Reeta KH; Gupta YK
    Biology (Basel); 2023 Jan; 12(1):. PubMed ID: 36671792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Nonprofit Drug Development Model Is Part of the Antimicrobial Resistance (AMR) Solution.
    Piddock LJV; Paccaud JP; O'Brien S; Childs M; Malpani R; Balasegaram M
    Clin Infect Dis; 2022 May; 74(10):1866-1871. PubMed ID: 34618892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reinventing the antimicrobial pipeline in response to the global crisis of antimicrobial-resistant infections.
    Singer AC; Kirchhelle C; Roberts AP
    F1000Res; 2019; 8():238. PubMed ID: 30906539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps.
    Simpkin VL; Renwick MJ; Kelly R; Mossialos E
    J Antibiot (Tokyo); 2017 Dec; 70(12):1087-1096. PubMed ID: 29089600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmaceutical effluent: a critical link in the interconnected ecosystem promoting antimicrobial resistance.
    Kotwani A; Joshi J; Kaloni D
    Environ Sci Pollut Res Int; 2021 Apr; 28(25):32111-24. PubMed ID: 33929671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibiotic resistant bacteria: current situation and treatment options to accelerate the development of a new antimicrobial arsenal.
    Tarín-Pelló A; Suay-García B; Pérez-Gracia MT
    Expert Rev Anti Infect Ther; 2022 Aug; 20(8):1095-1108. PubMed ID: 35576494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A narrative review on drug development for the management of antimicrobial- resistant infection crisis in Japan: the past, present, and future.
    Ohashi T; Nagashima M; Kawai N; Ohmagari N; Tateda K
    Expert Rev Anti Infect Ther; 2022 Dec; 20(12):1603-1614. PubMed ID: 36368311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Encouraging the Development of New Antibiotics: Are Financial Incentives the Right Way Forward? A Systematic Review and Case Study.
    Dutescu IA; Hillier SA
    Infect Drug Resist; 2021; 14():415-434. PubMed ID: 33574682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery research: the scientific challenge of finding new antibiotics.
    Livermore DM;
    J Antimicrob Chemother; 2011 Sep; 66(9):1941-4. PubMed ID: 21700626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Grant Framework as a Push Incentive to Stimulate Research and Development of New Antibiotics.
    Savic M; Årdal C
    J Law Med Ethics; 2018 Jun; 46(1_suppl):9-24. PubMed ID: 30146963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Artificial Intelligence and Antibiotic Discovery.
    David L; Brata AM; Mogosan C; Pop C; Czako Z; Muresan L; Ismaiel A; Dumitrascu DI; Leucuta DC; Stanculete MF; Iaru I; Popa SL
    Antibiotics (Basel); 2021 Nov; 10(11):. PubMed ID: 34827314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Buying Time: The AMR Action Fund and the State of Antibiotic Development in the United States 2020.
    Clancy CJ; Nguyen MH
    Open Forum Infect Dis; 2020 Nov; 7(11):ofaa464. PubMed ID: 33209952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An overview of the global antimicrobial resistance research and development hub and the current landscape.
    Mattar C; Edwards S; Baraldi E; Hood J
    Curr Opin Microbiol; 2020 Oct; 57():56-61. PubMed ID: 32777653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Innovation in Antimicrobial Resistance: The CARB-X Perspective.
    Alm RA; Gallant K
    ACS Infect Dis; 2020 Jun; 6(6):1317-1322. PubMed ID: 32202756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The alarming antimicrobial resistance in ESKAPEE pathogens: Can essential oils come to the rescue?
    Yu Z; Tang J; Khare T; Kumar V
    Fitoterapia; 2020 Jan; 140():104433. PubMed ID: 31760066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breaking antimicrobial resistance by disrupting extracytoplasmic protein folding.
    Furniss RCD; Kaderabkova N; Barker D; Bernal P; Maslova E; Antwi AAA; McNeil HE; Pugh HL; Dortet L; Blair JMA; Larrouy-Maumus G; McCarthy RR; Gonzalez D; Mavridou DAI
    Elife; 2022 Jan; 11():. PubMed ID: 35025730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. There is no market for new antibiotics: this allows an open approach to research and development.
    Klug DM; Idiris FIM; Blaskovich MAT; von Delft F; Dowson CG; Kirchhelle C; Roberts AP; Singer AC; Todd MH
    Wellcome Open Res; 2021; 6():146. PubMed ID: 34250265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and development of new antibacterial drugs: learning from experience?
    Jackson N; Czaplewski L; Piddock LJV
    J Antimicrob Chemother; 2018 Jun; 73(6):1452-1459. PubMed ID: 29438542
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.